Monica Morrow joins Memorial Sloan-Kettering Cancer Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Monica Morrow, MD, has joined the staff of Memorial Sloan-Kettering Cancer Center as chief of the Breast Service in the Department of Surgery. Dr. Morrow is also the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology, effective January 2009.

NEW YORK-Monica Morrow, MD, has joined the staff of Memorial Sloan-Kettering Cancer Center as chief of the Breast Service in the Department of Surgery. Dr. Morrow is also the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology, effective January 2009.

“We are very fortunate that Dr. Morrow, one of the country’s preeminent breast cancer surgeons, has joined our staff,” said Peter Scardino, MD, chair of the Department of Surgery. “Dr. Morrow is a superb physician, a distinguished spokesperson for breast cancer, and brings years of experience in surgical oncology to her new role.”

For more than 20 years, Dr. Morrow has been a leader in the treatment and prevention of breast cancer. After completing her surgical oncology training at MSKCC, she led the University of Chicago Hospital and Northwestern Memorial Hospital’s clinical breast programs. She served as co-principal investigator of Northwestern University’s Specialized Program of Research Excellence in Breast Cancer and, in 1996, received one of three inaugural grants from the Department of Defense Center for Excellence to increase access to modern multidisciplinary breast cancer care.

Prior to her appointment at MSKCC, she was chairman of surgical oncology at Fox Chase Cancer Center where she held the G. Willing “Wing” Pepper Chair in Cancer Research.

Recent Videos
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.